UCB Showcases Key Rheumatology Data at ACR Convergence 2021

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new data on its investigational IL-17A and IL-17F inhibitor, bimekizumab, and its TNF...

Related Keywords

Brussels , Bruxelles Capitale , Belgium , Nicole Herga , Certolizumab Pegol , J Clin Pharmacol , Antje Witte , Head Of Immunology Medical Affairs , Group Of Companies , American College Of Rheumatology Convergence , Twitter , Drug Administration , Term Improvements In Health , Source Ucb Inc , Jeffrey Stark , Long Term Safety , Ankylosing Spondylitis , Interim Results After , Ongoing Phase , Shows Sustained , Meaningful Long Term Improvements , Health Related Quality , Patient Reported Disease Activity , Ankylosing Spondylitis Receiving Bimekizumab , Post Hoc Analyses , Psoriatic Arthritis , Year Results , Tumor Necrosis Factor Inhibitor , Open Label Extension , Physical Function , Disease Impact , Related Quality , Psoriatic Arthritis Treated , Open Label Extension Study , Stringent Thresholds , Disease Control , Reduced Burden , Household Productivity , Term Safety , Active Non , Radiographic Axial Spondyloarthritis , Non Radiographic Axial Spondyloarthritis , Baselinec Reactive Protein Cut Offs , Post Hoc Analysis , Dose Reduction , Household Work Productivity , Further Results , Long Term Certolizumab Pegol Treatment , Deep Learning Algorithm , Active Axial , Tumor Necrosis Factor , Euronext Brussels , American College , Rheumatology Convergence , Active Axial Spondyloarthritis , Axial Spondyloarthritis , Dose Continuation , Arthritis Res , Ucb , Nc ,